314 HCP opinions, 12 recommendations.

A UK consensus on the optimal prescribing of medium strength triple therapy (ICS/LABA/LAMA) in adult asthma patients uncontrolled on an ICS/LABA.

Please note that the UK Consensus in adult asthma has been funded by Chiesi Ltd. The recommendations in the Consensus are not based on any specific product.

Trimbow® (beclometasone/formoterol/glycopyrronium) pMDI 87/5/9 is indicated for maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting β2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1